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Background
cART complexity is a major reason for non-adherence to
medications and, therefore, may impact treatment out-
come. The role of pill burden and dosing on virological
failure in ARV-naive HIV-positive patients achieving viro-
logic suppression under a tenofovir-based regimen has
not yet been assessed.
Methods
A total of 480 ART-naive patients were selected from the
GNOMO cohort. Incidence rate of viral rebound (VR =
first of two consecutive VL>50 cp/ml) was calculated as
number of events over PYFU and expressed at univariate
and multivariate analysis as incidence rate ratio (IRR).
Number of both pills and doses per day were used to
define three different types of regimens: twice-a-day regi-
mens (BID regimens); once-a-day regimens with <3 pills
per day (low-pill QD [lp-QD]); and once-a-day regimens
with >3 pills (high-pill QD [hp-QD]). Adjusted rates of
viral rebound were estimated by Poisson regression using
date of first HIV-RNA <50 c/ml as baseline. Follow-up was
censored at the date of VR, death, or loss to follow-up.
Summary of results
Male 74%; median pre-cART CD4 and HIV-RNA: 207/
mm3 (IQR 78–299) and 4.99 cp/ml (IQR 4.52–5.48),
respectively. Regimens were: 45.8% BID, 17.1% hp-QD,
37.1% lp-QD. Incidence rate of VR was 10.5 × 100 PYFU
(95% CI: 7.5–14.8) for BID, 7.4 × 100 PYFU (95% CI:
3.7–14.8) for hp-QD, and 5.8 (95% CI: 4.0–8.4) × 100
PYFU for lp-QD. At univariate analysis, taking as reference
the BID group, QD dosing was associated with a signifi-
cantly lower rate of VR (IRR 1.82; 95% CI 1.10–3.02).
However, when comparing the three groups together,
only lp-QD, but not hp-QD had a significantly lower risk
of VR (IRR 0.50; 95% CI 0.29–0.88) with respect to BID.
After adjusting for age, gender, time to first HIV-RNA <50
cp/ml, pre-cART CD4 and HIV-RNA, and daily pill bur-
den, as appropriate, a trend towards a reduced rate of VR
with respect to BID regimens was observed at the first
multivariate model for QD regimens (IRR 0.62; 95% CI
0.37–1.06) and at the second model for lp-QD regimens
(IRR 0.57; 95% CI 0.32–1.03). Of note, in both models
pre-cART CD4 >200/mm3 was independently associated
with reduced rate of VR (IRR 0.46; 95%CI 0.24–0.86)
when compared with CD4 <200/mm3.
Conclusion
Once-a-day dosing of tenofovir-based regimens, espe-
cially when combined with low daily pill burden, favour-
ably impacts on maintenance of virological response in
cART-naive patients. Higher baseline CD4 cell count inde-
pendently protects from loss of virological efficacy.
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